China’s SMIC, chipmaking stocks rally on report of advanced AI chip testing
Investing.com -- Nektar Therapeutics (NASDAQ:NKTR) stock surged 20% following the company’s announcement that it will present top-line data from its REZOLVE-AD Phase 2b clinical trial for atopic dermatitis treatment in June 2025.
The clinical-stage biotechnology firm revealed it will host an investor call and webcast on June 24, 2025, to review 16-week induction period results from the ongoing global study of rezpegaldesleukin, a regulatory T-cell proliferator being investigated for moderate-to-severe atopic dermatitis.
Nektar will release the data in a morning press release before presenting detailed findings during the webcast. The significant stock movement reflects investor interest in this potential treatment for atopic dermatitis, a chronic inflammatory skin condition affecting millions worldwide.
Rezpegaldesleukin represents one of Nektar’s key pipeline candidates as the company focuses on developing novel immunology therapies. The REZOLVE-AD trial is designed to evaluate the drug’s safety and efficacy in patients with moderate-to-severe forms of the skin condition.
The company stated that details on accessing the live webcast will be available in the morning press release and on Nektar’s website, with a replay available for at least 30 days following the event.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.